Solna, Sweden, 14 June 2024, Cell4Cure AB – a Swedish, private, cell therapy company world-leading in the field of dendritic cell-mediated tolerance – today announced that they have appointed Dr Rolf Ljung, Professor of Pediatrics at Lund University, Sweden as senior advisor for its first clinical program.

​

Cell4Cure AB appoints Professor Rolf Ljung, MD, PhD and Project Manager for the Pediatric Hematology Research Unit at Lund University as clinical advisor. The focus area for this research group is bleeding and coagulation disorders in children, in particular on clinical and genetic aspects of hemophilia. With his vast experience and expertise, professor Ljung will strategically support the implementation of the company’s first clinical program, Toler8, where the aim is to promote antigen-specific tolerance for FVIII in patients with hemophilia A having developed so called inhibitors, i.e. neutralizing antibodies, against FVIII. ItolDC-028 will be the first dendritic cell therapy, to be explored clinically from Cell4Cure’s technology platform. The technology platform in itself has several other potential uses beyond FVIII.

Christina Herder, CEO: “Professor Ljung has been an integral part in providing advice to us on the design of the Toler8 study which is now approved by EMA, the European Medicines Agency. His continued support in the program will be instrumental for a successful implementation. We are very grateful for his engagement.”

“The biggest clinical problem with hemophilia A is that about 30% develop inhibitors after treatment with factor VIII. We need a new strategy to solve this problem and Cell4Cure's concept is innovative and very interesting" comments Professor Rolf Ljung, Lund University.

​

For more information, please contact;

Christina Herder, CEO

Telephone: +46 703747156

E-mail: christina.herder@cell4cure.com

 

About Cell4Cure

Cell4Cure AB is a Swedish, privately held cell therapy company committed to the development of treatments for inducing of immune tolerance. The company’s proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance for the prevention or cure of diseases where the immune system is the enemy.

The company’s first clinical study, Toler8, is focusing on inducing tolerance to FVIII thereby preventing the occurrence of FVIII inhibitors, i.e. neutralizing antibodies, in hemophilia A patients.

Cell4Cure will as a first step deliver value to patients and shareholders by advancing this program to clinical proof of concept.

For more information visit www.cell4cure.com.